Profile
Charles Richter King was Senior Vice President of Research for GenVec, Inc. until April 15, 2009.
He joined GenVec in 1998.
Previously, he was Vice President of New Product Research for GenVec and Director of Drug Discovery for Oncologix.
Dr. King directed an experienced research group at the Georgetown University Medical School's Lombardi Cancer Research Center in Washington, DC, where he served as Associate Professor with the University's Department of Biochemistry.
He received a PhD in Biochemistry from Johns Hopkins University.
Former positions of Charles Richter King
| Companies | Position | End |
|---|---|---|
| GENVEC INC | Chief Tech/Sci/R&D Officer | 2009-04-14 |
| AGENUS INC. | Director/Board Member | - |
Training of Charles Richter King
| The Johns Hopkins University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| AGENUS INC. | Health Technology |
| Private companies | 1 |
|---|---|
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
- Stock Market
- Insiders
- Charles Richter King
